Cargando…

Saliva‐derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non‐small cell lung cancer

BACKGROUND: Both quantitative and qualitative aspects of plasma cell‐free DNA (plasma cfDNA, pcfDNA) have been well‐studied as potential biomarkers in non‐small cell lung cancer (NSCLC). Accumulating evidence has proven that saliva also has the potential for the detection and analysis of circulating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Shanshan, Song, Xingguo, Geng, Xinran, Liu, Lele, Ma, Hongxin, Wang, Xiujuan, Wei, Ling, Xie, Li, Song, Xianrang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775000/ https://www.ncbi.nlm.nih.gov/pubmed/31441578 http://dx.doi.org/10.1111/1759-7714.13178

Ejemplares similares

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019)

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018)

cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma
por: He, Qiong, et al.
Publicado: (2020)

Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma EGFR Mutations
por: Cho, Yong Gon, et al.
Publicado: (2023)

Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients
por: Boldrin, Elisa, et al.
Publicado: (2019)

Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients
por: Liu, Haiyan E., et al.
Publicado: (2020)

In silico error correction improves cfDNA mutation calling
por: Kim, Chang Sik, et al.
Publicado: (2019)

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay
por: Guo, Qiao-mei, et al.
Publicado: (2019)

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma
por: Marivel, A-M Joëlle, et al.
Publicado: (2023)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

Microfluidic Technologies for cfDNA Isolation and Analysis
por: Xu, Zheyun, et al.
Publicado: (2019)

cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?
por: Normanno, Nicola, et al.
Publicado: (2020)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023)

cfDNA methylome profiling for detection and subtyping of small cell lung cancers
por: Chemi, Francesca, et al.
Publicado: (2022)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
por: Bohers, Elodie, et al.
Publicado: (2021)

Plasma cfDNA predictors of established bacteraemic infection
por: Urosevic, Nadezda, et al.
Publicado: (2022)

Plasma cfDNA for the Diagnosis and Prognosis of Colorectal Cancer
por: Wu, Zhiwei, et al.
Publicado: (2022)

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
por: Rachiglio, Anna Maria, et al.
Publicado: (2022)

Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression
por: Sestokaite, Agne, et al.
Publicado: (2023)

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs
por: Ma, Li, et al.
Publicado: (2021)

Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
por: González de Aledo-Castillo, José Manuel, et al.
Publicado: (2021)

Comparison of the source and prognostic utility of cfDNA in trauma and sepsis
por: Jackson Chornenki, Nicholas L., et al.
Publicado: (2019)

Novel technologies in cfDNA analysis and potential utility in clinic
por: Li, Jie, et al.
Publicado: (2021)

cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome
por: Gerard, Laura, et al.
Publicado: (2021)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Verzè, Michela, et al.
Publicado: (2021)

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
por: Ntzifa, Aliki, et al.
Publicado: (2021)

Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients
por: Zhou, Xiaorong, et al.
Publicado: (2021)

Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer
por: Fujita, Kazutaka, et al.
Publicado: (2021)

CfDNA Measurement as a Diagnostic Tool for the Detection of Brain Somatic Mutations in Refractory Epilepsy
por: Mayo, Sonia, et al.
Publicado: (2022)

Validating quantitative PCR assays for cfDNA detection without DNA extraction in exercising SLE patients
por: Neuberger, Elmo W. I., et al.
Publicado: (2021)

MSIsensor-ct: microsatellite instability detection using cfDNA sequencing data
por: Han, Xinyin, et al.
Publicado: (2021)

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
por: Zulato, Elisabetta, et al.
Publicado: (2020)

Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA
por: Togneri, Fiona S, et al.
Publicado: (2016)

cfDNA screening and diagnosis of monogenic disorders – where are we heading?
por: Chiu, Eunice Ka Long, et al.
Publicado: (2018)

Detection of LINE-1 hypomethylation in cfDNA of Esophageal Adenocarcinoma Patients
por: Boldrin, Elisa, et al.
Publicado: (2020)

Impact of mosaicism ratio on positive predictive value of cfDNA screening
por: Rafalko, Jill M., et al.
Publicado: (2020)

cfDNA Changes in Maximal Exercises as a Sport Adaptation Predictor
por: Humińska-Lisowska, Kinga, et al.
Publicado: (2021)

Deep cfDNA fragment end profiling enables cancer detection
por: Zhitnyuk, Yulia V., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mib6vkvq0933ti516eq7h77rq4